Clinical trials
Phase 3 Arthritis, Psoriatic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
102 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 6 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 7 |
| 2014 | 10 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 7 |
| 2018 | 3 |
| 2019 | 9 |
| 2020 | 3 |
| 2021 | 8 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 8 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 74 |
| Active, not recruiting | 13 |
| Recruiting | 6 |
| Terminated | 5 |
| Not yet recruiting | 2 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 14 |
| Janssen Research & Development, LLC | 11 |
| Amgen | 9 |
| UCB Biopharma SRL | 8 |
| Pfizer | 6 |
| AbbVie | 5 |
| Bristol-Myers Squibb | 4 |
| Eli Lilly and Company | 4 |
| Takeda | 4 |
| Abbott | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Arthritis, Psoriatic | 102 |
| Psoriasis | 22 |
| Arthritis | 11 |
| Inflammation | 4 |
| Skin Diseases | 4 |
| Arthritis, Juvenile | 3 |
| Arthritis, Rheumatoid | 3 |
| Joint Diseases | 3 |
| Spondylarthritis | 3 |
| Spondylarthropathies | 3 |
Trials
Showing 1 to 25 of 102. Each trial links to its page on Pharma Observatory.
2 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.